左旋多巴诱发异动症大鼠模型基底节区谷氨酸脱羧酶表达的研究

目的 研究左旋多巴诱发异动症(LID)大鼠模型尾壳核、苍白球及黑质网状部谷氨酸脱羧酶(GAD)表达的变化。方法用免疫组织化学方法观测大鼠尾壳核、苍白球及黑质网状部GAD的表达变化，用辣根过氧化物酶(HRP)逆行示踪与免疫组织化学相结合的双重反应技术观测GAD的细胞分布状况。结果 LID大鼠较正常及非LID大鼠尾壳核区GAD明显增加，尤其在尾壳核外侧区增加更明显，且主要分布在纹状体黑质神经元内，苍白球区GAD明显增加，而黑质网状部GAD减少。结论 大鼠基底节区GAD表达变化与LID的发生有关，直接通路活动异常及基底节环路功能异常参与大鼠LID的发生。     

Adaptations in endocannabinoid signaling in response to repeated homotypic stress: a novel mechanism for stress habituation

Daily life stressors are a major environmental factor contributing to precipitation and exacerbation of mental illness. Animal models using repeated homotypic stress induce anxious and depressive phenotypes and are used to study the pathophysiology of affective disorders. Here we discuss data demonstrating that repeated homotypic stress produces temporally and anatomically distinct changes in endocannabinoid signaling components within stress-responsive brain regions. We also present evidence describing the neural and behavioral correlates of these adaptations in endocannabinoid signaling. These data support a role for endocannabinoid signaling in the central nervous system response to chronic, homotypic stress, and specifically in the process of stress–response habituation. The clinical implications of these findings for the pathophysiology and treatment of affective disorders are discussed.     

Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine

The opioid and cannabinoid systems co-operate to regulate physiological processes such as nociception and reward. The endocannabinoid system may be a component of the brain reward circuitry and thus play a role not only in cannabinoid tolerance/dependence, but also in dependence/withdrawal for other misused drugs. We provide evidence of a cannabinoid mechanism in an animal model of morphine drug-seeking behaviour, referred to as behavioural sensitization. The present study was designed to test the effects of the CB1 cannabinoid receptor antagonist SR141716A in two different phases of morphine sensitization (induction and expression) and to measure the brain contents of arachidonoylethanolamide (anandamide, AEA) and 2-arachidonoylglycerol (2-AG), the two main endogenous ligands for cannabinoid receptors in the different phases of morphine sensitization. The cannabinoid antagonist modified the signs of morphine sensitization when administered in the expression phase, whereas co-administration of SR141716A and morphine in the induction phase only slightly affected the behavioural responses, suggesting that CB1 receptor blockade attenuates the behavioural manifestations of morphine sensitization but not its development. AEA and 2-AG were affected differently by morphine during the two phases of behavioural sensitization. The alterations were in opposite directions and specific for the cerebral area analysed (caudate putamen, nucleus accumbens, hippocampus and prefrontal cortex). The results suggest that the endocannabinoid system undergoes profound changes during the different phases of sensitization to morphine in rats, providing a possible neurochemical basis for the previously observed cross-sensitization between opiates and cannabinoids.     

The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias

Intrastriatal transplantation of fetal ventral mesencephalon (VM) tissue provides the potential to alleviate motor symptoms of Parkinson's disease (PD) and levodopa-induced dyskinesia (LID). However, the degree of recovery varies among individuals with an incidence of "off-phase", graft-induced dyskinesia (GID) in some patients. We hypothesised that this variability is due to the heterogeneous nature of dopaminergic neurons in the transplant. We therefore investigated this in the unilateral 6-hydroxydopamine-lesioned rat model of PD. These animals were primed to develop LID and then transplanted with fetal VM into the caudal aspects of the striatum. No GID was observed but in a significant number of animals the transplants ameliorated LID. There was a correlation between the degree of behavioural and LID recovery with the number of A9 dopaminergic neurons in the transplant, based on their expression of a G-protein-coupled inward rectifying current potassium channel (Girk2). Furthermore, we showed that LID development is related to an abnormal expression profile of cyclin-dependent kinase 5 (Cdk5) and dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) in the striatum and that intrastriatal VM transplants normalised both Cdk5 expression and DARPP-32 phosphorylation in animals exhibiting functional improvement. These results suggest that an A9 dopaminergic neuron-enriched transplant may be the key to an effective PD cell replacement therapy through normalisation of the altered striatal expression of Cdk5/DARPP-32.     

A role for the endocannabinoid system in exercise‐induced spatial memory enhancement in mice

It is well known that physical exercise has positive effects on cognitive functions and hippocampal plasticity. However, the underlying mechanisms have remained to be further investigated. Here we investigated the hypothesis that the memory‐enhancement promoted by physical exercise relies on facilitation of the endocannabinoid system. We observed that the spatial memory tested in the object location paradigm did not persist in sedentary mice, but could be improved by 1 week of treadmill running. In addition, exercise up‐regulated CB₁ receptor and BDNF expression in the hippocampus. To verify if these changes required CB₁ activation, we treated the mice with the selective antagonist, AM251, before each period of physical activity. In line with our hypothesis, this drug prevented the exercise‐induced memory enhancement and BDNF expression. Furthermore, AM251 reduced CB₁ expression. To test if facilitating the endocannabinoid system signaling would mimic the alterations observed after exercise, we treated sedentary animals during 1 week with the anandamide‐hydrolysis inhibitor, URB597. Mice treated with this drug recognized the object in a new location and have increased levels of CB₁ and BDNF expression in the hippocampus, showing that potentiating the endocanabinoid system equally benefits memory. In conclusion, the favorable effects of exercise upon spatial memory and BDNF expression depend on facilitation of CB₁ receptor signaling, which can be mimic by inhibition of anandamide hydrolysis in sedentary animals. Our results suggest that, at least in part, the promnesic effect of the exercise is dependent of CB1 receptor activation and is mediated by BDNF. © 2013 Wiley Periodicals, Inc.     

Concomitant short- and long-duration response to levodopa in the 6-OHDA-lesioned rat: a behavioural and molecular study

The long-duration response (LDR) is a sustained improvement in parkinsonism due to chronic levodopa therapy and lasts after discontinuation of treatment. We have investigated the molecular changes that underlie the LDR in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion. Animals were treated for 22 days with levodopa or saline. Forelimb akinesia was evaluated prior and following a test dose of levodopa. Rotational behaviour was weekly evaluated. Levodopa induced an improvement in the parkinsonian limb akinesia that lasted for 48 h after withdrawal. A shortening in the duration of rotational behaviour was observed. After 3 days of washout, levodopa treatment maintained elevated striatal preproenkephalin mRNA expression, also inducing an increase in preprodynorphin (PDyn) and dopamine D-3 receptor mRNAs, but without any modification of the adenosine A(2A) mRNA expression induced by 6-OHDA. Levodopa reversed the lesion-induced increase in the expression of cytochrome oxidase mRNA in the subthalamic nucleus and glutamate decarboxylase mRNA in the pars reticulata of the substantia nigra. After 7 days of levodopa washout, the molecular markers show a decline in the basal ganglia evolving towards the parkinsonian state, being statistically significant for the striatal PDyn mRNA. This study characterizes the concomitant presence of the short-duration response and LDR to levodopa in the 6-OHDA model of parkinsonism and shows that the molecular changes induced by levodopa in the basal ganglia are not permanent and that this reversal after levodopa washout may be responsible for the gradual motor deterioration that characterize the LDR.     

Functional circuitry of the avian basal ganglia: implications for basal ganglia organization in stem amniotes

Histochemical, pathway tracing, and neuropeptide/neurotransmitter localization studies in birds, reptiles and mammals during the 1970s and 80s clearly showed that the telencephalon in all amniotes consists of a prominent ventrally situated subpallial region termed the basal ganglia, and a large overlying region involved in higher order information processing termed the pallium or cortex. These studies also showed that the basal ganglia in all extant amniote groups possessed neurochemically and hodologically distinct striatal and pallidal territories. More recently, studies of the localization of genes controlling regional brain development have confirmed the homology of the basal ganglia among amniotes. In our ongoing studies, we have identified several aspects of the functional organization of the basal ganglia that birds also share with mammals. These include: (1) an extensive glutamatergic "cortico"-striatal input and distinctive, cell-type specific localization of glutamate receptor subtypes; (2) an extensive, presumptively glutamatergic intralaminar thalamic input to striatal neurons; (3) an extensive dopaminergic input from the midbrain targeting both substance P (SP) type and enkephalin (ENK) type striatal projection neurons, with SP-type striatal neurons seemingly richer in the D-1 type dopamine receptor; and (4) SP+ and ENK+ striatal outputs giving rise to functionally distinct so-called direct and indirect motor output pathways, with the direct pathway having a pallido-thalamo-motor cortex loop and the indirect pathway relaying back to the direct circuit via the subthalamic nucleus. These findings suggest that the major aspects of the cellular organization and functional circuitry of the basal ganglia in stem amniotes were already as observed in living amniotes, as therefore presumably was its key role in movement control. Because the organization of the basal ganglia of anamniotes is clearly less elaborate than in amniotes, and because the basal ganglia and cortex in amniotes are clearly extensively interconnected structures, it seems likely that stem amniotes were characterized by a major step forward in the grade of telencephalic organization of both the basal ganglia and the pallium.     

Effects of thalamic lesion on the bilateral regulation of serotoninergic transmission in rat basal ganglia

Summary Unilateral kainic acid lesion of the rat centromedian-parafascicular complex (CM-PF) of the thalamus induced a decrease in the 5-hydroxyindole acetic acid/5-hydroxytryptamine ratio both in ipsi and contralateral striatum and substantia nigra, and an increase in both ipsi and contralateral frontal cerebral cortex. No change in apparent serotonin turnover was detected in anterior raphe nuclei. Serotonin synthesis, estimated by measuring 5-hydroxytryptophan accumulation after injection of a decarboxylase inhibitor, was not affected by the CM-PF lesion. The possible pathways involved in the control of serotonin transmission by CM-PF are discussed.     

Effects of nigrostriatal lesions on the levels of messenger RNAs encoding two isoforms of glutamate decarboxylase in the globus pallidus and entopeduncular nucleus of the rat.

The neurotransmitter gamma-aminobutyric acid (GABA) is present in efferent neurons of the striatum and of the pallidum, one of the main striatal target areas. Dopaminergic nigrostriatal neurons play a critical role in the regulation of GABAergic neurotransmission in the striatum. In the present study, we investigated their role in the regulation of glutamate-decarboxylase (GAD) mRNA expression in two divisions of the pallidum in rats: the globus pallidus and entopeduncular nucleus, equivalent to the external and internal pallidum, respectively, of primates. Dopaminergic neurons were lesioned by unilateral injections of 6-hydroxydopamine (6-OHDA) in the substantia nigra of adult rats. Two or 3 weeks after the lesion, frontal cryostat-cut sections of the brain were processed for in situ hybridization histochemistry with 35S-labeled RNA probes synthesized from cDNAs encoding two distinct isoforms of GAD of respective molecular weight 67,000 (GAD67) and 65,000 (GAD65). The number of labeled cells was determined, and intensity of labeling in individual cells was analyzed by computerized image analysis on emulsion radioautographs. In the globus pallidus, the number of labeled neurons and intensity of labeling per cell were increased on the side ipsilateral to the lesion as compared with control rats in sections hybridized with the GAD67 RNA probe. No changes were detected on the side contralateral to the lesion or in the levels of labeling for GAD65 mRNA. Confirming previous data, the level of labeling for GAD65 mRNA was much higher than for GAD67 mRNA in the entopeduncular nucleus of control rats. In rats with a 6-OHDA lesion, labeling for both GAD67 and GAD65 mRNAs was decreased on the side contralateral, but not ipsilateral, to the lesion, as compared with control rats. The results show that lesions of the nigrostriatal pathway in rats affect the levels of mRNAs encoding two distinct isoforms of GAD in neurons of the globus pallidus and entopeduncular nucleus differently. In addition, results in the entopeduncular nucleus further support a bilateral effect of unilateral dopaminergic lesions.     

Localization of N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) expression in mouse brain: A new perspective on N-acylethanolamines as neural signaling molecules

N-acylethanolamines (NAEs) are membrane-derived lipids that are utilized as signaling molecules in the nervous system (e.g., the endocannabinoid anandamide). An N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) that catalyzes formation of NAEs was recently identified as a member of the zinc metallohydrolase family of enzymes. NAPE-PLD(-/-) mice have greatly reduced brain levels of long-chain saturated NAEs but wild-type levels of polyunsaturated NAEs (e.g., anandamide), suggesting an important role for NAPE-PLD in the biosynthesis of at least a subset of endogenous NAEs in the mammalian nervous system. To provide a neuroanatomical basis for investigation of NAPE-PLD function, here we have analyzed expression of NAPE-PLD in the mouse brain using mRNA in situ hybridization and immunocytochemistry. NAPE-PLD(-/-) mice were utilized to establish the specificity of probes/antibodies used. The most striking feature of NAPE-PLD expression in the brain was in the dentate gyrus, where a strong mRNA signal was detected in granule cells. Accordingly, immunocytochemical analysis revealed intense NAPE-PLD immunoreactivity in the axons of granule cells (mossy fibers). Intense NAPE-PLD immunoreactivity was also detected in axons of the vomeronasal nerve that project to the accessory olfactory bulb. NAPE-PLD expression was detected in other brain regions (e.g., hippocampus, cortex, thalamus, hypothalamus), but the intensity of immunostaining was weaker than in mossy fibers. Collectively, the data obtained indicate that NAPE-PLD is expressed by specific populations of neurons in the brain and targeted to axonal processes. We suggest that NAEs generated by NAPE-PLD in axons may act as anterograde synaptic signaling molecules that regulate the activity of postsynaptic neurons.     

Neurotensin receptors in the rat striatum: lesion studies

The specific binding of [3H]neurotensin binding to the rat striatum was characterized and its localization investigated by using frontal cortex ablations and the neurotoxins kainic acid and 6-hydroxydopamine. Scatchard analysis indicated the existence of a single population of binding sites and the potencies of various neurotensin fragments in competing with [3H]neurotensin for its binding site were in good agreement with the potency values obtained in biological assays. The lesion studies indicated that more than 50% of striatal neurotensin receptors are localized on intrinsic neurones, approximately 30% on dopaminergic nerve terminals and 20% on corticostriatal nerve fibres.     

Effects of substantia nigra lesions on forebrain 2-deoxyglucose retention in the rat

A method was developed for the measurement of regional 2-deoxyglucose (2-DG) retention in rat brain by injecting tracer quantities of tritiated 2-DG intravenously, dissecting out individual brain regions, making extracts of the tissue, and counting aliquots of the extracts. This technique permits the separation of unreacted 2-DG from 2-deoxyglucose-6-phosphate (2-DGP) by ion exchange chromatography as well as the performance of other biochemical measurements on the extracts.Using this method, the effect of unilateral 6-hydroxydopamine (6-OHDA) lesions of the substantia nigra on 2-DG retention and 2-DGP formation by the striattum and the cerebral cortex was investigated. Animals were studied both 3 days and 2–4 weeks after lesioning. The location and efficacy of the lesions were verified histologically, behaviorally (by observing rotational behavior), and biochemically (by assay of striatal dopamine concentration or tyrosine hydroxylase activity). The lesions induced a mean asymmetry of less than 10% in 2-DG retention and in 2-DGP formation in striatum and cerebral cortex. This result was verified by [¹⁴C]2-DG autoradiography. Systemic administration of amphetamine (5 mg/kg) or apomorphine HBr (1.5 mg/kg) elicited rotational behavior, but did not induce a marked asymmetry of 2-DG retention in the regions studied. It is concluded that unilateral lesions of the nigrostriatal dopaminergic pathway have, at most, a modest effect on 2-DG retention by forebrain structures. We also conclude that vehicle injections may produce morphological and chemical evidence of brain injury, including small but reproducible changes in deoxyglucose retention.     

Quantitation of nerve terminal populations: synaptic vesicle-associated proteins as markers for synaptic density in the rat neostriatum

This study has assessed the contributions of the corticostriatal fibers, the ascending striatopetal fibers, and the intrinsic neostriatal neurons to the nerve terminal population found in the rat neostriatum (caudatoputamen). For this purpose, we have analysed the levels of two different synaptic vesicle-associated proteins, synapsin I and protein p38 (also called synaptophysin), in the neostriatum after specific lesions. Our results indicate that 45-50% of the synaptic vesicle proteins in the rat neostriatum derive from the corticostriatal fibers, that approximately 25-30% of the synaptic vesicle proteins are present in kainic acid-sensitive structures, presumably intrinsic terminals and local collaterals, and that ascending fibers contain 20-25% of the vesicle-associated proteins in the neostriatum. These three neuronal populations therefore comprise 95-100% of the synaptic vesicle-associated proteins in the rat neostriatum, and thus make up most of the nerve terminals in this brain region. The results, which are in general agreement with previous morphometric studies on the rat basal ganglia, therefore indicate that nerve terminals in the central nervous system can be quantitated by use of these biochemical nerve terminal markers. The results also indicate that a somewhat higher percentage of neostriatal nerve terminals belongs to the corticostriatal fibers that previously believed.     

Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea

Background Genetic variation in endocannabinoid metabolism is associated with colonic transit in irritable bowel syndrome (IBS) with diarrhea (IBS‐D). The nonselective cannabinoid (CB) receptor agonist, dronabinol (DRO), reduced fasting colonic motility in nonconstipated IBS. FAAH and CNR1 variants influenced DRO’s effects on colonic motility. Our aims were: (i) to compare dose‐related effects of DRO to placebo (PLA) on gut transit in IBS‐D, and (ii) to examine influence of genetic variations in CB mechanisms on DRO’s transit effects. Methods Thirty‐six IBS‐D volunteers were randomized (double‐blind, concealed allocation) to twice per day PLA (n = 13), DRO 2.5 mg (n = 10), or DRO 5 mg (n = 13) for 2 days. We assessed gastric, small bowel, and colonic transit by validated radioscintigraphy and genotyped the single nucleotide polymorphisms CNR1 rs806378 and FAAH rs324420. Data analysis utilized a dominant genetic model. Key Results Overall treatment effects of DRO on gastric, small bowel, or colonic transit were not detected. CNR1 rs806378 CT/TT was associated with a modest delay in colonic transit at 24 h compared with CC (P = 0.13 for differential treatment effects on postminus pretreatment changes in colonic transit by genotype). No significant interaction of treatment with FAAH rs324420 was detected. Conclusions & Inferences Overall, DRO 2.5 or 5 mg twice per day for 2 days had no effect on gut transit in IBS‐D. There appears to be a treatment‐by‐genotype effect, whereby DRO preferentially delays colonic transit in those with the CNR1 rs806378 CT/TT genotypes. Further study of CB pharmacogenetics may help identify a subset of IBS‐D patients most likely to benefit from CB agonist therapy.     

Effects of fibroblast transplantation into the internal pallidum on levodopa-induced dyskinesias in parkinsonian non-human primates

Recent studies have shown that fibroblast transplantation can modify the activity of basal ganglia networks in models of Parkinson's disease.To determine its effects on parkinsonian motor symptoms,we performed autologous dermal fibroblast transplantation into the internal pallidum(GPi) in two parkinsonian rhesus monkeys with stable levodopainduced dyskinesias(LIDs).Levodopa responses were assessed every week after transplantation for three months.A reduction of between 58%and 64%in total LIDs on the contralateral side was observed in both animals.No clear LID changes were observed on the ipsilateral side.These effects lasted the entire3-month period in one monkey,but declined after6-8 weeks in the other.The antiparkinsonian effects of levodopa did not diminish.The results of this pilot study indicate that fibroblast transplantation into the GPi may have beneficial effects on LIDs and warrant further investigation for potential therapeutic use.     

Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: Histochemical and neurochemical analysis

The impact of intracerebroventricular administration of 6-hydroxydopamine (6-HDA) on the dopamine (DA)-containing nigrostriatal projection was determined by regional histochemical and biochemical analyses. One week postinjection, we observed that tyrosine hydroxylase (TH)-positive terminals were almost completely absent from the medial portion of striatum but gradually increased in density toward the lateral margin of this structure. A similar gradient was indicated by fluorescence histochemistry and biochemical analyses of DA. In contrast, the 6-HDA-induced changes in TH activity and in dihydroxyphenylacetic acid content were less severe and showed little or no medial-to-lateral gradient. These high levels of TH activity and DOPAC content, relative to local DA concentrations, suggest an increase in the synthesis and release of DA from residual terminals that may serve to compensate for the brain damage. By 4 months postlesion, both histochemical and biochemical analyses indicated the presence of more DA terminals in striatum than there had been one week postlesion. This change was most markedly obvious in the medial striatum, which had been almost completely devoid of terminals at one week postlesion. Retrograde tracing experiments revealed that terminals appearing in the medial striatum at 4 months postlesion arise from the same region of the substantia nigra that innervates the medial striatum in the intact animal. Thus, no change in the topographic relation between substantia nigra and striatum occurred as a result of the lesion.     

MK-801对左旋多巴诱导异动症大鼠模型基底节区神经元活性的影响

目的:研究NMDA(N-methyl-D-aspartate)受体拮抗剂MK-801对左旋多巴诱导的帕金森病大鼠异常不自主运动行为学及其基底节区Fos表达的影响,探讨谷氨酸对长期左旋多巴治疗后帕金森病大鼠基底节输出通路活性改变的影响。方法:帕金森病大鼠给予左旋多巴治疗28d,第29d左旋多巴治疗前15min腹腔注射MK-801一次。观察其行为学变化,并用免疫组织化学方法观察尾壳核和苍白球Fos表达情况。结果:长期间断左旋多巴治疗后,帕金森病大鼠出现刻板运动和进行性增加的对侧旋转等行为学改变。提前用MK-801抑制了其刻板动作,而增加了对侧旋转行为。与左旋多巴治疗组比较,MK-80l治疗组损毁侧尾壳核区Fos表达明显增多而苍白球区Fos表达明显减少。结论:慢性间断性左旋多巴治疗诱导帕金森病大鼠异常不自主运动和旋转期缩短是帕金森病患者左旋多巴诱导异动症和疗效减退的啮齿类动物模型,谷氨酸在其发生机制中发挥重要作用,NMDA受体拮抗剂可能通过逆转直接通路的活动而抑制异动症和疗效减退的发生。     

Anatomy and physiology of the basal ganglia: implications for DBS in psychiatry

The basal ganglia have been a target for neuromodulation surgery since Russell Meyers' pioneering works in the late 1930s. Contemporary movement disorder surgery on the brain has evolved from empiric observations on movement behavior after neurological lesions. So too has the development of psychiatric surgical procedures followed the observation of lesions in the brain on cognitive and affective behavior. Just as deep brain stimulation (DBS) has revolutionized the practice of movement disorder surgery, its application to psychiatric illness has become the cutting edge of functional and restorative neurosurgery. The fundamental concept of the cortico-striatal-pallido-thalamocortical loop will be explored in the context of psychiatric disorders. DBS targeting this circuitry appears from initial evidence in obsessive-compulsive disorder (OCD) to be a promising option for patients with neuropsychiatric illness resistant to conventional therapies. Further exploring the anatomic interconnectivity of the physiologically relevant cortical and subcortical areas will inevitably lead to better applications of DBS for the treatment of OCD, major depression (MD) and potentially for other psychiatric disorders. Implementing such therapies optimally will require the creation of treatment centers with specialized expertise in the psychiatric, neurosurgical, and ethical issues that arise with these populations.     

The acute effects of 6-hydroxydopamine treatment on noradrenergic function in the rat hippocampus in vitro

The electrophysiological consequences of in vitro treatment with 6-hydroxydopamine (6-OHDA) were examined in the CA1 region of the rat hippocampal slice. In control slices, norepinephrine (NE) increased the amplitude of the population spike response elicited by synaptic stimulation of hippocampal pyramidal neurons with a threshold of approximately 5 microM. When hippocampal slices were pretreated with 500 microM 6-OHDA for 10 min, perfusion with a subthreshold concentration of NE (0.5 microM) produced responses similar to those observed with a 10-fold higher concentration of NE in untreated slices. Baseline electrophysiological responses were unchanged following the 6-OHDA exposure. The potentiation of the response to NE by in vitro pretreatment with 6-OHDA was accompanied by a greater than 40% decrease in NE content and greater than 90% decrease in [3H]NE accumulation. In vivo treatment with 6-OHDA or N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride (DSP4) also potentiated the electrophysiological response to NE in a manner similar to that observed with acute in vitro 6-OHDA pretreatment. This action does not appear to be due to development of beta-adrenergic receptor supersensitivity, because the apparent potency of isoproterenol in increasing the population spike amplitude was unaffected. These data suggest that the increase in the potency of NE in slices pretreated with 6-OHDA is due to the rapid disruption of the high-affinity NE uptake mechanism characteristic of noradrenergic nerve terminals.     

Regional brain catecholamine levels and the development of hypertension in the spontaneously hypertensive rat: the effect of 6-hydroxydopamine

To investigate the role of central catecholaminergic pathways in the development of hypertension in the spontaneously hypertensive rat (SHR) the effects of intracerebroventricular (i.c.v.) injections of 6-hydroxydopamine (6-OHDA) were compared with those of local injections near the main ascending noradrenergic pathways. The parameters studied were systolic blood pressure, heart rate and regional catecholamine concentrations in micropunched brain areas. I.c.v. treatment with 6-OHDA (three 200 micrograms injections) of young SHR attenuated the development of hypertension and caused widespread depletion of noradrenaline and to a lesser extent of dopamine and adrenaline. 6-OHDA-induced lesions of the dorsal and ventral noradrenergic bundles did not affect the rise in blood pressure but induced a depletion of forebrain noradrenaline comparable to that after the i.c.v. treatment. Dopamine and adrenaline levels were, however, not substantially affected. These results suggest that forebrain noradrenergic innervation may not be of major importance for the development of hypertension in the SHR.